Cancer Vaccine Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

Description

The Global Cancer Vaccine Market will witness over 11.2% CAGR between 2024 and 2032, driven by increased investments in research and development leading to innovative and more effective vaccines. There is a surge in awareness about cancer prevention and early detection, backed by the rising incidences of cancer globally.

In June 2024, BioNTech and DualityBio's BNT324/DB-1311 received FDA Fast Track designation for treating metastatic castration-resistant prostate cancer. The designation, based on promising Phase 1/2 trial data, will facilitate expedited development and regulatory review. The advancements in biotechnology and personalized medicine are enabling the creation of targeted vaccines, improving efficacy and patient outcomes. Collaborative efforts between public and private sectors are also accelerating vaccine development and distribution, propelling cancer vaccine market expansion.

The cancer vaccine industry is grouped based on type, technology, application, end-use, and region.

The therapeutic segment will account for a notable market share by 2032, due to their potential to offer personalized treatment options and improve patient outcomes. These vaccines aim to stimulate the immune system to target and destroy cancer cells more effectively, offering a complementary approach to existing therapies. As personalized medicine gains traction, patients and healthcare providers are increasingly seeking treatments that can be tailored to individual tumor profiles. The growing interest in precision oncology, combined with advancements in vaccine technology and clinical trial successes, is driving the demand for therapeutic vaccines in the cancer treatment landscape.

The prostate cancer segment will register a noteworthy growth rate from 2024 to 2032, boosting the need for specialized immunotherapies in combating this prevalent disease. As prostate cancer remains a common cancer among men, there is a substantial patient population in need of effective treatment options. The emphasis on prostate cancer vaccines has spurred research and development efforts, attracted investment, and driven innovation. Successful outcomes and advancements in clinical trials for prostate cancer vaccines is boosting market expansion.

North America cancer vaccine industry will hold a remarkable revenue share by 2032, driven by high healthcare spending and a strong emphasis on cancer research and innovation. The region benefits from advanced healthcare infrastructure, leading to faster adoption of new treatments and technologies. The increased public awareness about cancer prevention and treatment, coupled with supportive government policies and funding for cancer research, contribute to market expansion. The presence of pharmaceutical companies and research institutions in North America fosters a conducive environment for the development and commercialization of cutting-edge cancer vaccines.

Product Code: 10285

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rising prevalence of cancer
  - 3.2.1.2 Advancements in biotechnology and immunotherapy
  - 3.2.1.3 Growing demand for personalized medicine
  - 3.2.1.4 Rising geriatric population
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 High cost associated with cancer vaccine development
  - 3.2.2.2 Side effects and safety concerns
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscape
- 3.5.1 Core technologies
- 3.5.2 Adjacent technologies
3.6 Pricing analysis, 2023
- 3.6.1 By region
- 3.6.2 By key player
3.7 Future market trends
3.8 Pipeline analysis
3.9 Porter's analysis
3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Preventive vaccine
5.3 Therapeutic vaccine

Chapter 6 Market Estimates and Forecast, By Technology, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Recombinant cancer vaccine
6.3 Whole-cell cancer vaccine
6.4 Viral vector and DNA cancer vaccine
6.5 Antigen/adjuvant cancer vaccine
6.6 Other technologies

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Prostate cancer
7.3 Cervical cancer
7.4 Colorectal cancer
7.5 Lung cancer
7.6 Melanoma
7.7 Other applications

Chapter 8 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Hospitals
8.3 Cancer treatment centers
8.4 Academic and research institutes
8.5 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

10.1 Ayala Pharmaceuticals
10.2 AstraZeneca PLC
10.3 Amgen Inc.
10.4 Bristol-Myers Squibb Company
10.5 Dynavax Technologies Corporation
10.6 Dendreon Pharmaceuticals LLC
10.7 Ferring Pharmaceuticals
10.8 F. Hoffmann-La Roche Ltd
10.9 GeneReach Biotechnology Corp.
10.10 GSK plc
10.11 EOM Pharmaceutical Holdings, Inc.
10.12 Merck and Co., Inc.
10.13 Moderna, Inc.
10.14 OSG Immunotherapeutics
10.15 Sanofi